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Purpose:  The present study was undertaken to develop a validated, rapid, simple and economic 
stability indicating reverse phase HPLC method for estimating meloxicam (MLX) in bulk and commercial 
preparations.  
Method: Reversed phase chromatographic analysis was performed on a C18 Hi Q Sil column  with 
acetonitrile-water-glacial acetic acid [55:40:5 (% v/v)] at a flow rate of 1ml/min and detection wavelength 
of 355 nm. System suitability tests essential for the assurance of quality performance of the method 
were performed. The drug was subjected to stress degradation studies under acidic, basic and oxidative 
conditions.  The method was validated for accuracy, precision, reproducibility, specificity, robustness,  
limit of detection (LOD) and limit of quantification (LOQ) , as per International Conference on 
Harmonization (ICH)  guidelines.  
Results: A single sharp peak was obtained for MLX at Rt of 6.8 ± 0.01min. The polynomial regression 
data for the calibration plots exhibited good linear relationship (r = 0.9995) over a concentration range of 
4–20µg/ml and the linear regression equation was y = 57257.38x + 3443.07. Accuracy ranged from 
99.27 to 100.78% and the % coefficient of variation (CV) for both intra-day and inter-day precision was 
less than 2%. MLX showed minor degradation peak in acidic conditions at Rt of 2.24min. The LOD and 
LOQ values were 360 ng/ml and 510 ng/ml, respectively.  
Conclusion: The proposed method gave good resolution of MLX and its degradants. System suitability 
tests and statistical analysis performed prove that the method is precise, accurate and reproducible, and 
hence can be employed for routine analysis of MLX in bulk and commercial formulations. 
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INTRODUCTION 
 
Meloxicam (MLX), is an oxicam derivative 
and a member of the enolic acid group of 
non-steroidal anti-inflammatory drugs 
(NSAIDs)
1,2
. It is chemically designated as 4-
hydroxy-2-methyl–N-(5- methyl–2–thiazolyl) -
2H -1,2-benzothiazine–3-carboxamide-1,1-
dioxide. MLX exhibits anti-inflammatory, 
analgesic and anti-pyretic activities, 
especially in various chronic conditions, like 
osteoarthritis, rheumatoid arthritis, pauciar-
ticular and polyarticular course juvenile 
rheumatoid arthritis
3,4
. The mechanism of 
action of MLX is believed to be due to 
inhibition of prostaglandin synthesis, primarily 
via inhibition of cyclooxygenase-2 (COX-2). 
In contrast with other NSAIDs, it has neither 






















are reported for 
the analysis of MLX in pharmaceuticals. 
HPLC is the most commonly used method for 
analysis of MLX. An extensive literature 
survey reveals few HPLC methods for 
estimation of MLX in pharmaceutical dosage 
forms as well as biological fluids; however, 
not all of these are stability indicating and 
some of them make use of buffer in the 
mobile phase.  Most of the reported methods 
either do not include stress degradation 
studies or are not completely validated, and 





Method validation is an essential step in drug 
analysis. The process confirms that the 
analytical procedure employed for the 
analysis is suitable for its intended use and 
shows reliability of the results produced by 
any method.  
 
The primary objective of the present work 
was thus to develop and validate a stability 
indicating HPLC method for MLX, which 
could also be employed for the routine 
analysis of the drug in pharmaceutical 
dosage forms. In the method proposed, the 
mobile phase was used directly for  the 
dilution of the formulation after filtration, and 
then further used for analysis. Direct use of 
the mobile phase as diluent for formulations 
in quantitative analysis minimizes errors that 
occur during tedious extraction procedures. 









MLX was received as a gift from Unichem 
Lab. Ltd., Mumbai, India. Acetonitrile (HPLC 
– grade) was purchased from Merck, India. 
Millipore purification system was used for 
high purity water. All other chemicals and 
reagents employed were of analytical grade 





The chromatograph system comprised of a 
Jasco PU-980 pump equipped with a Jasco 
UV-975 detector and a Rheodyne injector 
with a 20-microlitre loop. Data integration was 
done using a Borwin software package 
V1.21. Samples were injected into a Hi-Q-Sil 
C-18 column (4.6 x 250mm, 5 µ particle size). 
Mobile phase flow rate was 1ml/min. The 





Initial trial experiments were conducted, with 
a view to select a suitable solvent system for 
the accurate estimation of the drug and to 
achieve good resolution between the drug 
and the degradation products. The suitability 
of the mobile phase was decided on the basis 
of the sensitivity of the assay, suitability for 
stability studies, time required for the 
analysis, ease of preparation, and use of 
readily available cost-effective solvents. 
These included methanol–water (50:50 % 
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v/v), acetonitrile–water, (50:50 % v/v), 
acetonitrile-water (60:40 %v/v), acetonitrile-
water-glacial acetic acid (54:44:2 % v/v) and  
acetonitrile-water-glacial acetic acid (55:40:5 
% v/v). A mobile phase system comprising of 
acetonitrile-water-glacial acetic acid (55:40:5 
% v/v) was found to be optimum. The same 
solvent mixture was used for the extraction of 
the drug from the formulation containing 
excipients. The solvents were mixed, filtered 
through a membrane filter of 0.45 micron 






A series of standard curves were prepared 
over a concentration range of 4 - 20 µg/ml 
from a stock solution of MLX (1mg/ml) in 
acetonitrile. Dilutions were prepared in the 
mobile phase: acetonitrile-water-glacial acetic 
acid (55:40:5 %v/v). The procedure for 
analysis follows that described earlier under 
the subsection, ‘Chromatography method’. 
The data from peak area versus drug 
concentration plots were treated by linear 
least square regression analysis. The 
standard curves were evaluated for intra-day 
and inter-day reproducibility. Each 




Precision is the measure of how close the 
data values are to each other for a number of 
measurements under the same analytical 
conditions. The three components of 
precision, i.e., repeatability, intermediate 
precision and reproducibility, in accordance 





Injection repeatability:  Five injections of 12 
µg/mL solution of MLX were analyzed and 
%RSD calculated for injection repeatability.  
Intra-day variation: Measurement of intra-day 
variation of MLX solutions at three different 
concentrations (8, 12 and 16 µg/mL) was 
carried out by injecting the samples on the 
same day at different time intervals.  
Analysis repeatability: It was obtained by 
determining the relative standard deviation 
(RSD) of replicate samples (n=3) of the 
accuracy study.  
 
Intermediate precision (Inter-day variation) 
 
Measurement of inter-day variation of MLX 
solutions at three different concentrations (8, 
12 and 16 µg/mL) in triplicate on three 
consecutive days determined the 
intermediate precision.  
 
 Reproducibility  
 
The reproducibility of the method was 
checked by determining precision on the 
same instrument, but by a different analyst. 
For both intra-day and inter-day variation, 
solutions of MLX at three different 
concentrations (8, 12, and 16 µg/mL) were 




Accuracy is the measure of how close the 
experimental value is to the true value. 
Recovery studies by the standard addition 
method were performed with a view to justify 
the accuracy of the proposed method. 
Previously analyzed samples of MLX (12 
µg/ml) were spiked with 50, 100, and 150% 
extra MLX standard and the mixtures were 
analyzed by the proposed method. The 
experiment was performed in triplicate. 
Recovery (%), RSD (%) and standard error of 
mean (SEM) were calculated for each 
concentration.  
 
LOD and LOQ  
 
In order to estimate the limit of detection 
(LOD) and limit of quantitation (LOQ) values, 
the blank sample was injected six times and 
the peak area of this blank was calculated as 
noise level. The LOD was calculated as three 
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times the noise level while ten times the 




The robustness of the method was 
determined to assess the effect of small but 
deliberate variation of the chromatographic 
conditions on the determination of MLX. 
Robustness was determined by using 
reagents from two different lots and two 
different manufacturers. 
 
Sample solution stability  
 
The stability of the drug in solution during 
analysis was determined by repeated 
analysis of samples during the course of 
experimentation on the same day and also 
after storage of the drug solution for 72 h 
under laboratory bench conditions (25 ± 1 °C) 
and under refrigeration (8 ± 0.5 °C). An 
accurately weighed quantity of the pure drug 
was dissolved in acetonitrile and suitably 
diluted with mobile phase to get a final 
concentration of 12 µg/ml. The solution was 
subjected to HPLC analysis immediately and 




The specificity of the method was determined 
by exposing the sample solution (12 µg/mL) 
to acidic (0.1 M HCl), basic (0.1 M NaOH), 




) stress conditions. 
The samples were refluxed for 10 h at 100ºC, 
filtered and analyzed.  
 
System suitability tests 
 
The chromatographic systems used for 
analyses must pass the system suitability 
limits before sample analysis can commence. 
The capacity factor (K), injection repeatability 
(as described earlier in the subsection, 
‘Precision’), tailing factor (T), theoretical plate 
number (N) and resolution (Rs) for the 
principal peak and its degradation product 
were the parameters tested on a 12  µg/mL  
sample of MLX to assist the accuracy and 
precision of the developed HPLC system. 
 
Analysis of MLX in marketed tablets 
 
Ten tablets (strength: 15 mg/tablet) were 
crushed and triturated well in a mortar. A 
powder sample, equivalent to 15mg of MLX, 
was accurately weighed and transferred to a 
25ml volumetric flask. The drug was 
extracted into acetonitrile and mixed 
thoroughly for 30 min using a sonicator. The 
solution was filtered through 0.45 micron pore 
filter after making up the volume, adequately 
diluted with mobile phase and analyzed by 
the proposed HPLC method. The possibility 





The r value for the calibration plot, SD, RSD, 
and SEM were determined using Microsoft 




Method development  
 
Acetonitrile-water-glacial acetic acid (55:40:5 
%v/v) was selected as the optimum mobile 
phase. Under these conditions the retention 
time and tailing factor were 6.8 ± 0.01 min 
and 1.13 respectively. A typical 






Peak area versus drug concentration was 
plotted to construct a standard curve for MLX. 
The polynomial regression for the calibration 
plots showed good linear relationship with 
coefficient of correlation, r = 0.9995 ± 0.0092; 
slope = 57257.38 ± 165.74 and intercept = 
3443.07 ± 97.56 (n = 6) over the 
concentration range studied. The range of 
reliable quantification was set at 4 – 20 µg/ml 
as no significant difference was observed in 
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the slopes of the standard curves in this 
range. The linear regression data for the 
calibration plot is indicative of a good linear 
relationship between peak area and 
concentration over a wide range. The 
correlation coefficient was indicative of high 
significance. The low values of the standard 
deviation, the standard error of slope, and the 
intercept of the ordinate showed the 




Precision was measured in accordance with 
ICH recommendations. Five consecutive 
injections of 12 µg/mL solution of MLX by the 
proposed method showed excellent injection 
repeatability with RSD of only 0.47%. 
Repeatability of sample injection was 
determined as intra-day variation while inter-
mediate precision was determined by 
measuring inter-day variation for triplicate 
determination of MLX at three different 
concentrations. The results of the 
determination of repeatability, intermediate 
precision and reproducibility are listed in 
Table 1. Reproducibility was checked by 
measuring the precision of the proposed 
method with analysis being performed by 
another person. The low RSD values indicate 





The recovery of the method, determined by 
spiking a previously analyzed test solution 
with additional drug standard solution, was 
found to be in the range of 99.27 – 100.78%. 
The values of recovery (%), RSD (%) and 
SEM listed in Table 2 indicate the method is 
accurate.  
 
Table 1: Precision of method 
 
Intra- day and inter-day precision 
Repeatability (Intra- day precision) Intermediate precision (Inter- day) Conc. 











8 452863 ± 2963 1710.74 0.654 450238 ± 8645 4991.34 1.92 
12 670795 ± 5896 3404.15 0.879 669125 ± 5463 3154.16 0.816 
16 897092 ± 7368 4254.04 0.821 892560 ± 4756 2745.96 0.533 
Reproducibility 
Repeatability (Intra- day precision) Intermediate precision (Inter- day) Conc. 









8 458216 ± 5132 2963.05 1.120 449822 ± 1384 799.08 0.308 
12 687125 ± 6861 3961.32 0.998 671527 ± 4974 2871.82 0.741 
16 894234 ± 4893 2825.06 0.547 901681 ± 4566 2636.26 0.506 
*n = 3 
†SEM = standard error of mean 
 
Table 2: Accuracy of method  
 
Amount (%) of 














0 12 11.94 ± 0.182 99.51 1.52 0.105 
50 18 18.14 ± 0.137 100.78 0.76 0.079 
100 24 23.91 ± 0.201 99.63 0.84 0.116 
150 30 29.78 ± 0.164 99.27 0.55 0.094 
*n = 3 
†SEM = standard error of mean 
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Detection and Quantification limits  
 
The limit of detection was found to be 360 
ng/ml where the drug could be detected 
without any noise. The limit of quantification 
was 510 ng/ml. This indicated the method 
can be used for detection and quantification 





There was no significant change in the 
retention time of MLX when reagents 
(acetonitrile and glacial acetic acid) from 
different lots and different manufacturers 
were used. The concentration of the solution 
analyzed was 12 µg/mL and the % RSD 
ranged from 0.078 to 1.286 %. The low 
values of the RSD indicated the robustness 




There was no significant change in analyte 
composition (sample concentration = 12 
µg/mL) over a period of 72 h. The mean  
RSD between peak areas, for the samples 
stored under refrigeration  (8 ± 1°C) and at 
laboratory temperature (25 ± 1°C) was found 
to be 0.990% and 0.771% respectively, 
suggesting that the drug solution can be 
stored without any degradation over the time 




The specificity of the method was determined 
by exposing 12 µg/mL sample solutions of 
MLX to stress conditions, i.e., 0.1 M HCl, 0.1 




. There was no 
degradation of MLX in the presence of 0.1 M 




 and no significant change 
in peak area and retention time of MLX was 
observed (Fig 1). However, in the presence 
of 0.1N HCl, it was found that there was a 
substantial change in the peak area of MLX, 
but not in the retention time. Chromatograms 
obtained from MLX after treatment with 0.1 M 




are shown in 
Fig 2. A degradation product (Fig 1D) eluted 
with a retention time of 2.24 ± 0.03 min. The 
results from stress testing, including 
separation of the degradation product and 
quantification of MLX after exposure to stress 




Figure 1: Chromatographic illustration of 
degradation products of MLX; (A) MLX;(B) 





























Figure 2: Proposed degradation pathway for 
meloxicam 
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System suitability tests 
 
The results of the system suitability tests 
assure the adequacy of the proposed HPLC 
method for routine analysis of MLX. The 
capacity factor (k) was found to be 1.86, 
indicating that the MLX peak is well resolved 
with respect to the void volume. The RSD of 
five consecutive injections performed under 
the precision test was found to be 0.47% and 
thus shows good injection repeatability. The 
tailing factor (T) for MLX peak was found to 
be 1.13, reflecting good peak symmetry.  The 
resolution (Rs) for the principle peak and its 
acid degradation product was found to be 
6.22, indicating good separation of the drug 
from its degradation product. The theoretical 
plate number (N) was found to be 2466, thus 
demonstrating good column efficiency. 
 
Analysis of MLX from marketed tablets 
 
A single peak was observed at the retention 
time of MLX when a suitably diluted solution 
of the tablet formulation was chromato-
graphed. No interaction was observed 
between MLX and excipients present in the 
tablets. The MLX content was found to be 
99.46% and the RSD was 0.94%. The low 
RSD indicated the suitability of this method 
for routine analysis of MLX in pharmaceutical 




The final decision on mobile phase 
composition and flow rate was made on the 
basis of peak shape, peak area, tailing factor, 
baseline drift and time required for analysis. 
The solvent system selected [acetonitrile-
water-glacial acetic acid (55:40:5 %v/v)] gave 
good resolution of degraded product and 
drug peak.  No internal standard was used 
because no extraction or separation step was 
involved. Methanol-water (50:50 %v/v) did 
not furnish a sharp, well-defined peak and but  
effected a high tailing factor (1.82). Other 
mobile phases tried resulted either in much 
lower sensitivity, delayed retention time or 
poor peak shapes, and so were not 
considered. 
  
The proposed HPLC method of analysis was 
also found to be precise and accurate, as 
depicted by the statistical data of analysis. 
High values of correlation coefficients and 
small values of intercepts validated the 
linearity of the calibration plots and 
obedience to Beer’s laws. The RSD values 
and the slopes and intercepts of the 
calibration graphs indicate the high 
reproducibility of the proposed method. The 
method was also found to be robust as there 
was no significant change in the peak area, 
peak shape and retention time of MLX. 
Furthermore, the low values of LOD and LOQ 
indicate that the method can be employed 
over a wide concentration range for linearity. 
This method is also highly sensitive and 
could effectively separate the drug from its 
degraded product. MLX is a thiazolyl 
substituted benzothiazine carboxamide. 
Solution of MLX is stable at room 
temperature and when refluxed at 100ºC for 
10 h with a strong base (NaOH) or  hydrogen 
peroxide solution. However, when refluxed at 
100ºC with a strong acid (HCl) for 10h, 
hydrolysis of the amide group takes place, 
resulting in the formation of the 
corresponding carboxylic acid and amine (Rt 
of 2.24 min.). Fig 2 represents the proposed 
degradation pathway. 
 
As the reported method could effectively 
separate the drug from its degraded product, 
it can be employed as a stability indicating 
one. The system suitability tests performed 
verified the resolution, column efficiency and 
repeatability of the chromatographic system 
and ensured that the equipment, electronics, 
and analytical operations for the samples 
analyzed could be constituted as an integral 




The HPLC method developed is accurate, 
precise, reproducible, specific, and stability-
indicating. The method is linear over a wide 
Bandarkar & Vavia 
Trop J Pharm Res, June 2009; 8 (3):  264 
range, economical and utilizes a mobile 
phase which can be easily prepared. All 
these factors make this method suitable for 
quantification of MLX in bulk drugs and in 
pharmaceutical dosage forms. It can 
therefore be concluded that use of the 
method can save much time and money and 
it can be used even in small laboratories with 
very high accuracy and precision. The 
method can also be used for the routine 
analysis of MLX in bulk preparations of the 
drug and in pharmaceutical dosage forms 
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